Atara to Suspend Development of Protein Energy Wasting Treatment

December 18, 2015

Atara Biotherapeutics is suspending further development of PINTA 745 for the treatment of protein energy wasting in patients with end-stage renal disease after the candidate fell short of its goal in a Phase 2 trial.

Atara says it will shift its focus to its portfolio of clinical stage oncology and immunotherapy product candidates.